Teva After the Print: Short Sellers Rebuild, Options Reset

TEVA has just reported Q3 results, and the positioning data tells a different story from the pre-earnings optimism that defined the previous two weeks.

The most notable shift is in short interest. Estimated short shares rose 21.7% over the past week to around 29.8 million, reversing the steady decline from the early-October peak above 36 million. That is a meaningful rebuild in a single week, though it still leaves the position well below where it stood a month ago, when shorts held over 34 million shares. The borrow market is not signalling any stress to accompany that move: availability remains extremely loose at 1,144% of short interest, meaning there are more than eleven shares available to borrow for every one currently shorted. Cost to borrow edged up 20% on the week to 0.56%, but that remains a low absolute level with no sign of a squeeze. What the data points to is fresh short conviction being expressed in a market where the stock has run, not a forced or panicked position rebuild.

Options positioning has reset toward neutral after the pre-earnings call skew. The put/call ratio moved back up to 0.51, essentially in line with its 20-day average of 0.51 and sitting just below flat on a z-score basis. That is a marked reversal from the readings below 0.49 seen in the days before the Q3 print, when call-side demand was near its most lopsided level of the past year. The lopsided call positioning has unwound, and the market is no longer leaning as hard into the upside thesis.

Valuation multiples have expanded modestly alongside the stock's climb. The PE is running at 14.3x, up roughly 0.4 points over the past month, and EV/EBITDA has moved to 11.7x. Both have drifted higher through October as the stock gained 6%, suggesting the market has been willing to pay more for the turnaround story. The earnings yield ranks in the 85th percentile relative to the broader universe, which means the stock is not expensive on that measure despite the momentum-driven multiple expansion. The ORTEX short score has eased to 41.7 from a recent peak of 43.9 on October 21, sitting at the mid-point of its range and consistent with a stock that generates neither strong bearish conviction nor obvious squeeze pressure.

Retail attention has picked up sharply. The ORTEX alt data layer flags Wikipedia views running 3.65 standard deviations above their 90-day norm as of October 20, by far the strongest attention signal in the dataset. This measures retail interest, not a revenue indicator, but the spike aligns with the pre-earnings period and the stock's move to its 52-week high. BlackRock added 27.9 million shares in the quarter ending September 30, bringing its stake to 8.4% of shares outstanding, the largest institutional holder by some margin. WCM Investment Management and State Street both added modestly in the same period, though Lingotto trimmed by 2.7 million shares.

The next scheduled earnings event is February 10, 2027. With the Q3 print now out, the market's attention turns to whether the biosimilars pipeline and debt reduction progress justify the multiples the stock now carries, particularly with short sellers having just added meaningfully in the week the results landed.